IMI Launches
NF Call

Our vision is to end NF

The Children's Tumor Foundation's mission is to drive research, expand knowledge, and advance care for the NF community.


Research for a cure

Since its formation, the Children’s Tumor Foundation has been crucial to the development of solid scientific data about the genetic disorder neurofibromatosis (NF). Thanks to the generosity of our donors and supporters, we are breaking through barriers and forging the pathway that will lead to a cure.

Get to know our NF Heroes

Latest News

IMI Launches Significant Neurofibromatosis Call for Patient-Centric Drug Development

Jun 27, 2018, Posted in Collaborations, Latest News, Outside Opportunities, Press Release, Science

The Children’s Tumor Foundation is an Associated Partner of the European-based Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI), a jointly funded partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), will soon issue a call for an integrated research platform enabling patient-centric drug development.

More >

An 11-Year-Old’s Vision to Find a Cure

Jul 18, 2018

In 2014, when Chloe Peterson of Yakima Valley, Washington was just 11 years old, while her tween peers were busy checking out Disney’s Frozen, Chloe was finding a way to make a difference. She says, “I wanted to do something to spread awareness for local charities and causes close to my heart.”

More >

End NF with Ian Desmond

Jul 9, 2018, Posted in Awareness, Community

Going to a Colorado Rockies baseball game?

Whether you are planning to attend a Rockies game at home (at Coors Field in Denver) or on the road, you may be able to meet NF Champion Ian Desmond to express your gratitude for his support through awareness to the NF cause and personal donations for research to Children's Tumor Foundation!

More >

Photo Contest 2018 Winner Announced

Jul 2, 2018

We’re excited to announce the winner of the 2018 NF Awareness Month I Know a Fighter photo contest!

More >

Get the latest news and announcements in our newsletter: